A study to find out how healthy people tolerate a new drug called S221237.
CL1-221237-002
Phase 1 other active
Quick answer
A study to find out how healthy people tolerate a new drug called S221237. for Parkinson disease (PD) is a Phase 1 program (other) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Institut für biomedizinische Analytik NMR-Imaging GmbH
- Indication
- Parkinson disease (PD)
- Phase
- Phase 1
- Modality
- other
- Status
- active